comparemela.com

Latest Breaking News On - Hepion pharmaceutical - Page 7 : comparemela.com

Hepion Pharmaceuticals Announces Adjournment of Annual

EDISON, N.J., June 25, 2021 (GLOBE NEWSWIRE) Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the.

United-states
Philadelphia
Pennsylvania
America
American
Stephen-kilmer
Exchange-commission
Hepion-pharmaceuticals
Philadelphia-stock-transfer-inc
Hepion-pharmaceuticals-investor-relations
Hepion-pharmaceuticals-inc
Nasdaq

Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a ‘AMBITION’ . Hepion Pharmaceuticals, Inc.May 6, 2021 GMT EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (“NASH”), today announced that it has completed recruitment for its Phase 2a ‘AMBITION’ clinical trial, with all NASH patients in the 225 mg CRV431 dosing cohort now enrolled. “Over the past few months, the COVID-19 pandemic, compounded by the inclement weather experienced at some of our clinical trial sites in Texas, which resulted in power outages, presented difficulties in the recruitment of subjects for the second and final dosing cohort for our Phase 2a NASH trial,” said Dr. Robert Fos

Texas
United-states
Stephen-kilmer
Toddm-hobbs
Robert-foster
Exchange-commission
Hepion-pharmaceuticals
Hepion-pharmaceuticals-investor-relations
Hepion-pharmaceuticals-inc
Nasdaq
Chief-medical
Artificial-intelligence

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals to Present on CRV431 and AI-POW at NASH-TAG 2021

Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals to Present on CRV431 and AI-POW at NASH-TAG 2021 EDISON, NJ / ACCESSWIRE / March 11, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)( Hepion ), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ( NASH ) and liver disease, today announced that it will present at the NASH-TAG 2021 Conference, being held virtually on March 11-13. The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of NASH and liver fibrosis.

Stephen-kilmer
Robert-foster
Exchange-commission
Company-phase
Hepion-pharmaceuticals
Hepion-pharmaceuticals-investor-relations
Hepion-pharmaceuticals-inc
Nasdaq
Artificial-intelligence
New-pharmacological
Private-securities-litigation-reform-act
Hepion-pharmaceutical

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021
theusnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theusnews.com Daily Mail and Mail on Sunday newspapers.

Stephen-kilmer
Robert-foster
Exchange-commission
Company-phase
Hepion-pharmaceuticals
Hepion-pharmaceuticals-investor-relations
Hepion-pharmaceuticals-inc
Nasdaq
Artificial-intelligence
New-pharmacological
Private-securities-litigation-reform-act
Hepion-pharmaceutical

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021

Hepion Pharmaceuticals to Present on CRV431 and AI-POW(TM) at NASH-TAG 2021
saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.

Stephen-kilmer
Robert-foster
Exchange-commission
Company-phase
Hepion-pharmaceuticals
Hepion-pharmaceuticals-investor-relations
Hepion-pharmaceuticals-inc
Nasdaq
Artificial-intelligence
New-pharmacological
Private-securities-litigation-reform-act
Hepion-pharmaceutical
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.